Effect of Shenmai Injection on L-type Calcium Current of Diaphragmatic Muscle in Rats

Diaphragmaticmuscleisanimportantrespiratorymuscle,anddiaphragmaticfatiguecanleadtomanydisorders .Onlyintherecent 2 0 yearshavethesys temicresearchesbeen performedtoinvestigatethefunctionofdiaphragmanditspathophysiology .Di aphragmaticfatiguecanbeinducedby…     

Effect of SJAMP on ATP Release of Platelet

Ｓｅｃｒｅｔｉｏｎｏｆｐｌａｔｅｌｅｔｓｉｓａｎａｇｏｎｉｓｔ－ｉｎ－ｄｕｃｅｄｒｅｓｐｏｎｓｅ，ｗｈｉｃｈｉｓｏｆｉｍｐｏｒｔａｎｃｅｆｏｒｔｈｅｅｎｈａｎｃｅｍｅｎｔｏｆｐｌａｔｅｌｅｔａｃｔｉｖａｔｉｏｎａｎｄｆｏｒｔｈｅｖａｒｉｏｕｓｅｆｅｃ...     

Effects of microinjection of L-glutamate into locus coeruleus complex area on respiration

Summary The experiments were performed on 55 rabbits vagotomied, anesthetized with urethane and immobilized with flaxedil. Injection of L-glutamate (L-glu) into the locus coeruleus complex (Lc-Sc) area led to a marked increase in respiratory frequency (RF) and phrenic nerve discharge rate (phr. d) (16±3.5% and 6.5±2.5%;P<0.01 andP<0.05, respectively), a decrease in inspiratory and expiratory duration, and no obvious change in blood pressure (Bp) was observed. While prazosin (0.5 μg/μl), yohimbin (4 (μg/μl) and propranolol (2μg/μl) were preinjected into the nuclei tractus solitraii (NTS) respectively, the above-mentioned effects of L-glu on respiration was blocked. These results indicate that the excitation of neurons in the Lc-Sc can induce an increase in RF and phr d and the excitative effect of L-glu on RF was mediated by α₁,α₂ and β-receptors in the NTS, while the effect on phrd was mediated differently. This project was supported by grant no. 3870190 from the National Natural Sciences Foundation of China.     

Experimental Study on the Inhibitory Effects of Verapamil on the Proliferation of Meningiomas Cells

In order to investigate the effects of verapamil on the proliferation of meningiomas cells in vitro and in vivo, the cultured meningiomas cells were cultured with verapamil at different concen-trations for 24 h and the inhibitory effects of verapamil on cell proliferation were observed by MTT method. The meningiomas model was established by implanting the newly removed tumor fragments into the nude mice subcutaneously. The nude mice with tumors were divided into two groups: vera-pamil-treated group and control group. Tumor volumes were measured and after 12 weeks the tumors were taken out and examined histologically. The expression of proliferating cell nuclear antigen (PCNA) in the tumors was detected by using immunohistochemistry. It was found that verapamil could inhibit the growth of cultured meningiomas cells in a concentration-dependant manner. The in-hibitory effect could be observed in the concentration of 1 μmol/L verapamil and the most obvious effects appeared in the concentration of 100 μmol/L. Tumor volume in the verapamiltreated group was obviously smaller than that in the control group (211.40±5.50 vs 163.94±3.62, P<0.01) and the expression of PCNA was also lower (1.52±0.24 vs 2.86±0.53, P<0.05). Tumor inhibition rate was about 22.45%. It was suggested that verapamil could inhibit the proliferation and growth of men-ingiomas cells in vitro and in vivo.     

Endothelial nitric oxide synthase traffic inducer in the umbilical vessels of the patients with pre-eclampsia

The expression of endothelial nitric oxide synthase traffic inducer （NOSTRIN） was examined in the umbilical vessels of the patients with pre-eclampsia （PE） to explore its possible role in the pathogenesis of PE. The NOSTR1N rnRNA in umbilical tissues was determined by RT-PCR. The eNOS activity in umbilical vessels was spectrophotometrically detected. NO2 /NO3, the stable metabolic end products of NO, was measured by using nitrate reductase. RT-PCR showed that the expression level of NOSTRIN was significantly higher in women with PE than in the normal group （P〈0.01）. The activity of eNOS was significantly decreased in PE group [（12.83±3.61） U/mg] than in normal group [（21.72±3.83） U/mg] （P〈0.01）. The level of NO2-/NO3- in PE patients （27.53±7.48） pmol/mg was significantly lower than that of normal group （54.27±9.53） μmol/mg （P〈0.01）. The significant negative correlation existed between the expression of NOSTRIN and the activity of eNOS in umbilical vessels of women with PE （r=-0.58, P〈0.01）. It was concluded that the level of NOSTR1N expression was increased in umbilical vessel of women with PE, indicating that it may be involved in the pathogenesis of PE.     

Effect of Nuclear Factor-κB on Airway Remodeling in Asthmatic Rats

Summary In order to investigate the effect of nuclear factor-κB (NF-κB) on airway remodeling in asthmatic rats. 18 Wistar rats were divided into three groups: asthmatic group: pyrrolidine dithiocarbamate (PDTC) group, in which rats were injected intraperitoneally with NF-κB specific inhibitor PDTC (100 mg/kg) before ovalbumin (OVA) challenge; control group. The NF-κB activity and the expression of inhibitory protein κBα (I-κBα) in airway were detected by electrophoretic mobility shift assay (EMSA). Western blot and immunohistochemistry respectively. The infiltration of inflammatory cells, the number of Goblet cells, the area of collagen and smooth muscle in airway were measured by means of image analysis system. The results showed that with the up-regulation of airway NF-κB activity in asthmatic group, the number of goblet cells (3.08±0.86/100 μm basement membrane (BM)), the area of collagen (24.71±4.24 μm²/μm BM) and smooth muscle (13.81±2.11 μm²/μmBM) in airway were significantly increased (P<0.05) as compared with control group (0.14±0.05/100μmBM. 14.31±3.16 μm²/μm BM and 7.67±2.35 μm²/μm BM respectively) and PDTC group (0.33±0.14/100 μmBM, 18.16±2.85 μm²/μm BM and 8.95±2.16 μm²/μm BM respectively). However, there was no significant difference between PDTC group and control group (P>0.05). It was concluded that the activity of NF-κB is increased in airway of asthmatic rats. Inhibition of NF-κB, activation can attenuate constructional changes in asthma airway, suggesting NF-κB may contribute to asthmatic airway remodeling. XU Shuyun, female, born in 1970, M. D. Ph. D. This project was supported by a grant from Foundation for University Key Teacher by the Ministry of Education (2000 year).     

Expression of Endothelial Nitric Oxide Synthase Traffic Inducer in the Placenta of Pregnancy Induced Hypertension

Endothelial nitric oxide synthase traffic induc-er(NOSTRIN),a58kD(1kD=0.9921ku)pro-tein with complete unknown function that was i-dentified using the yeast two-hybrid system byZi mmermannet al[1],and Zi mmermann demon-strated that NOSTRIN over-expression induced aprofound redistribution of eNOS fromthe plasmamembrane to vesicle-like structures matching theNOSTRIN pattern and at the same ti me led to asignificant inhibition of NO release[1].WhetherNOSTRIN do involve in the mechani…     

Experimental Studies on immune－Complex in Situ Type Glomerulonephritis in Rabbits Treated with Mai－Luo－Tong and Natural Indig

(孙世澜)(易惠萍)(汪琼玲)(黄寿珍)(刘晓城)ＥｘｐｅｒｉｍｅｎｔａｌＳｔｕｄｉｅｓｏｎｉｍｍｕｎｅ－ＣｏｍｐｌｅｘｉｎＳｉｔｕＴｙｐｅＧｌｏｍｅｒｕｌｏｎｅｐｈｒｉｔｉｓｉｎＲａｂｂｉｔｓＴｒｅａｔｅｄｗｉｔｈＭａｉ－Ｌｕｏ－ＴｏｎｇａｎｄＮａｔｕｒａｌ...     

Reversal of multidrug resistance and inhibition of phosphorylation of AKT in human ovarian cancer cell line by wild-type PTEN gene

Summary The reversing effect of wild-type PTEN gene on resistance of C13K cells to cisplatin and its inhibitory effect on the phosphorylation of protein kinase B (AKT) were studied. The expression of PTEN mRNA and protein in OV2008 cells and C13K cells were semi-quantitatively detected by using RT-PCR and Western blotting. Recombinant eukaryotic expression plasmid containing human wild-type PTEN gene was transfected into C13K cells by lipofectamine2000. The expression of PTEN mRNA was monitored by RT-PCR and the expression of PTEN, Akt, p-Akt protein were analyzed by Western blotting in PTEN-transfected and non-transfected C13K cells. Proliferation and chemosensitivity of cells to DDP were measured by MTT, and cell apoptosis was detected by flow cytometry after treatment with cisplatin. The expression of PTEN mRNA and protein in OV2008 cells were significantly higher than those in C13K cells. After transfection with PTEN gene for 48 h, the expression of PTEN mRNA and protein in C13K cells were 2.04 ± 0.10, 0.94 ± 0.04 respectively and the expression of p-Akt protein (0.94 ± 0.07) was lower than those in control groups (1.68 ± 0.14, 1.66 ± 0.10) (P < 0.05). The IC₅₀ of DDP to C13K cells transfected with PTEN (7.2 ± 0.3 μmol/L) was obviously lower than those of empty-vector transfected cells and non-transfected cells (12.7 ± 0.4 μmol/l, 13.0 ± 0.3 μmol/L) (P<0.05). The apopototis ratio of wild-type PTEN-transfected, empty vector transfected and non-transfected C13K cells were (41.65 ± 0.87)%, (18.61 ± 0.70)% and (15.28 ± 0.80)% respectively, and the difference was statistically significant (P<0.05). PTEN gene plays an important role in ovarian cancer multidrug resistance. Transfection of PTEN could increase the expression of PTEN and restore drug sensitivity to cisplatin in human ovarian cancer cell line C13K with multidrug-resistance by decreasing the expression of p-Akt. This project was supported by a grant from the National Natural Sciences Foundation of China (No. 30571950) and National Key Basic Research Program Foundation (NO.2002CB513107).     

Effects of Phorbol-12,13-dibuterate on Sodium Currents and Potassium Currents in Rat Trigeminal Ganglion Neurons

The effects of phorbol-12,13-dibuterate (PDBu) on total sodium current (INa-total), tet-rodotoxin-resistant sodium current (INa-TTXr), 4-AP-sensitive potassium current (IA) and TEA-sensitive potassium current (IK) in trigeminal ganglion (TG) neurons were investigated. Whole-cell patch clamp techniques were used to record ion currents in cultured TG neurons of rats. Results revealed that 0.5 μmol/L PDBu reduced the amplitude of INa-total by (38.3±4.5)% (n=6, P<0.05), but neither the G-V curve (control: V0.5 =-17.1±4.3 mV, k=7.4±1.3; PDBu: V0.5=-15.9±5.9 mV, k=5.9±1.4; n=6, P>0.05) nor the inactivation rate constant (control: 3.6±0.9 ms; PDBu: 3.6±0.8 ms; n=6, P>0.05) was altered. 0.5 μmol/L PDBu could significantly increase the amplitude of INa-TTXr by (37.2± 3.2)% (n=9, P<0.05) without affecting the G-V curve (control: V0.5=-14.7±6.0 mV, k=6.9± 1.4; PDBu: V0.5=-11.1±5.3 mV, k=8.1±1.5; n=5, P>0.05) or the inactivation rate constant (control: 4.6±0.6 ms; PDBu: 4.2±0.5 ms; n=5, P>0.05). 0.5 μmol/L PDBu inhibited IK by (15.6±5.0) % (n=16, P<0.05), and V0.5 was significantly altered from - 4.7±1.4 mV to -7.9 ±1.8 mV (n=16, P<0.05). IA was not significantly affected by PDBu, 0.5 μmol/L PDBu decreased IA by only (0.3±3.2)% (n=5, P>0.05). It was concluded that PDBu inhibited INa-total but enhanced INa-TTXr, and inhibited IK without affecting IA. These data suggested that the activation of PKC pathway could exert the actions.     

Antagonistic effects of trasilast on proliferation and collagen synthesis induced by TGF-\sB<Subscript>2</Subscript> in cultured human trabecular meshwork cellsin cultured human trabecular meshwork cells

Summary Whether tranilast had antagonistic effect on proliferation inhibition and collagen synthesis promotion induced by TGF-\sB₂ in cultured human trabecular meshwork cells was investigated. Suspension of 1×10⁴ cultured human trabecular meshwork cells of 3–5 passage was distributed in each well of a 96-well disk and divided into control group and experimental group. After 24 h, 0 μg/ml (control), 12.5 μg/ml, 25 μg/ml, 50μg/ml tranilast with 3.2 ng/ml TGF-\sB₂ were added into the incubation medium. Another 24 h later, proliferation and collagen synthesis in cultured human trabecular meshwork cells were examined respectively by using tetrazolium-based semiautomated colormetric (MTT) assay and³H-proline incorporation with liquid scintillation technique. The results showed absorbance (A) values of the experimental groups were 0.9036±0.3017, 1.1361±0.1352, 1.2457±0.1524 according to the different concentrations of tranilast, and 0.8956±0.1903 of the control group. In comparison with the control group, 25 μg/ml (q=3.23,P<0.05), 50 μg/ml (q′=4.70,P<0.01) tranilast significantly antagonized the decrease of theA values induced by TGF-\sB₂ in the cultured human trabecular meshowrk cells. In comparison with the control group [817.37±124.21 cpm/10⁴ cells], 12.5 μg/ml (620.33±80.46 cpm/10⁴ cells,q′=4.26,P<0.05), 25 μg/ml (59.4.58±88.13 cpm/10⁴ cells,q′=4.81,P<0.01), 50 μg/ml (418.64±67.90 cpm/10⁴ cells,q′=8.62,P<0.01) tranilast significantly inhibited the incorporation of³H-proline into the cultured human trabecular meshwork cells promoted by TGF-\sB₂ in a dose-dependent manner. It was concluded that tranilast had the antagonistic effect on the proliferation inhibition and collagen synthesis promotion induced by TGF-\sB₂ in the cultured human trabecular meshwork cells. Da Banghong, female, born in 1973, Resident. This project was supported by a grant from the National Natural Sciences Foundation of China (No. 38970758).     

脑供血动脉支架置入术前不同抗血小板治疗方案的初步疗效评价

目的 采用血栓弹力图（TEG）检测拟行颅内外动脉支架置入术前患者双联抗血小板治疗后血小板抑制情况,寻找术前最佳给药时间、给药剂量,以指导临床。方法 据既往是否有单纯阿司匹林服用史及术前阿司匹林不同给药剂量,将我院93例患者,分为4组,分别为:无服药史低剂量组(阿司匹林100 mg+氯吡格雷75 mg)、无服药史高剂量组(阿司匹林300 mg+氯吡格雷75 mg)、有服药史低剂量组、有服药史高剂量组。TEG检测服药后1 d和服药后3 d花生四烯酸(AA)通路血小板抑制率和二磷酸腺苷(ADP)通路血小板抑制率。结果 不同时间点分析:既往无服药史低剂量组,服药后3 d血小板抑制率\[AA: (89.09±17.42)%, ADP: (57.02±23.97)%\]高于服药后1 d\[AA:(82.24±22.25)%,ADP: (49.62±25.44)%\],差异有统计学意义(P<0.05);既往无服药史高剂量组,服药后3 d血小板抑制率\[AA: (95.06±8.05)%,ADP: (47.76±24.95)%\]高于服药后1 d\[AA:(88.88±14.66)%,ADP: (36.17±22.71)%\],差异有统计学意义(P<0.05)。不同剂量分析:相同服药时间下,无服药史低剂量组与高剂量组、有服药史低剂量组与高剂量组,AA通路抑制率差异均无统计学意义。结论 对既往未服用过阿司匹林的脑血管病患者,支架置入术前抗血小板治疗3 d比治疗1 d可达到更好的血小板抑制效果,而低剂量与高剂量间血小板抑制效果相当。     

Effect of Yangqixue Qufengshi Recipe on rheumatoid arthritis model mice under different genetic backgrounds

Objective: To study the effect of Yangqixue Qufengshi Recipe (YQXQFS) on rheumatoid arthritis (RA) model mice under different genetic backgrounds.Methods: Collagen Induced Arthritis (CIA) were established on HLA-DR4 transgenic (TG) mice and non-transgenic (NTG) mice, which partly were raised with YQXQFS, and the onset day of CIA, the level of type II collagen (C II)-reactive antibodies and the pathological scores of CIA were assessed.Results: Under HLA-DR4 TG background (compared with NTG mice), the earlier onset day of CIA (11.22 ± 3.35 days vs 16.56 ± 4.75 days,P<0.05) and higher level of C II-reactive antibodies (0.2274 ± 0. 1390 μg/ml vs 0. 1101 ± 0.0560 μg/ml,P<0.05) were observed, but the pathological scores of CIA remained unchange. YQXQFS could not influence the onset day of CIA and the level of CII -reactive antibodies, but had a certain effect on the total pathological scores (6.56 ± 3.43 scores vs 11.11 ± 5.64 scores) and bone erosion (0.22 ± 0.44 scores vs 1.67 ± 1.50 scores) of CIA on NTG mice (P<0.05), NTG YQXQFS group compared with NTG experimental group.Conclusion: YQXQFS had a certain effect on RA model, but had no significant effect on HLA-DR4 related CIA.     

Measurement of platelet-activating factor in human blood by high performance thin layer chromatography and its clinical application

Summary Platelet-activating factor (PAF) present in the blood of the patients with chronic pulmonary heart disease and asthma has been detected by high performance thin layer chromatography (HPTLC). The patients with chronic pulmonary heart disease accompanied by carbon dioxide retention (PaCO₂>6.67 kPa) have a higher level of PAF in blood (0. 75 ±0. 27 μg/ml) than those who have no carbon dioxide retention (PaCO₂<6.67 kPa, PAF 0.41 ±0. 25 μg/ml) and those in the normal control group (0.45 ±0.20 μg/ml), withP<0.05 in all. The patients with asthma have a higher PAF in blood (0.83±0. 05 μg/ml) than those in the control group (P < 0.005). These findings suggest that PAF plays an important role in episodes of chronic pulmonary heart disease and asthma.     

Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention

Background Whether two clopidogrel pretreatment strategies prior to elective percutaneous coronary intervention （PCI）： a 300 mg loading dose （LD） in clopidogrel naive patients and a 75 mg maintenance dose （MD） once daily in patients on chronic clopidogrel therapy play the same role in the platelet inhibition in Chinese with different CYP2C19 genotypes remains unknown. We aim to evaluate the impact on platelet inhibition by clopidogrel pretreatment strategy and its interaction effect with CYP2C19 genotype. Methods Chinese patients undergoing PCI （n=840） were assigned to 2x2 groups in the trial according to different clopidogrel pretreatment strategies （470 patients in LD, 370 patients in MD） and CYP2C19 genotypes （494 carriers of any CYP2C19 ＊2 or ＊3 loss-of-function allele, 346 non-carriers）. The primary outcome was platelet aggregation （PA） as measured by the 10 umol/L adenosine diphosphate induced light transmission aggregation. Results Compared with MD group, LD strategy showed a significantly higher PA-（（59.22＋11.67）% vs. （52.83±12.17）%, P 〈0.01）, similar PA difference was observed in CYP2C19 loss-of-function carriers compared with non-carriers （（59.41±10.91）% vs. （52.10±12.90）%, P 〈0.01）. LD patients in either the CYP2C19 loss-of-function allele carrier or non- carrier group showed a significantly higher PA compared with MD group （（61.50±10.61）% vs. （56.84±10.74）%, P 〈0.01; （56.06±12.34）% vs. （46.88±11.78）%, P 〈0.01, respectively）. A quantitative interaction effect was observed between clopidogrel pretreatment strategy and CYP2C19 genotype （P=0.001）. Conclusion The 300 mg LD strategy results in a decreased effect on platelet inhibition compared with the 75 mg MD in Chinese patients receiving clopidogrel prior to PCI, especially in the CYP2C19 ＊2 or ＊3 loss-of-function allele non-carriers. （ClinicalTrials.gov number NCT01710436） Chin tided J 2014;127 （14）： 2571-2577     

Redistribution of platelet membrane glycoprotein iv and release of intracellular α-granule thrombospondin in patients with chronic myelogenous leukemia

Summary The redistribution of platelet membrane glycoprotein IV (GPIV) and the release of intracellular α-granule thrombospondin (TSP) were examined and the inhibition of β-thromboglobulin (β-TG) and platelet factor 4 (PF4) in patients with chronic myelogenous leukemia (CML) was observed and quantitation of β-TG and PF4 in sera was conducted. GPIV in inactive platelet from CML was 36080± 17010 molecules/platelet as compared with 13190±4810 from the controls (P< 0.01). No abnormality was found in the distribution of platelet membrane GPI_b and GPII_b/III,(P> 0.05). The GPIV redistribution on active platelet membrane induced thrombin (IU/ml) from CML and healthy donors was 44320 ±32310 and 22800± 12700 molecules/platelet respectively (P< 0.01). The difference in the release of intracellular α-granule TSP between CML and the control group was not found (P> 0.05). There was no direct correlation between GPIV expression and TSP binding after platelet activation. The high levels of β-TG and PF4 in sera inhibited release of intracellular α-granule TSPin vitro. These results indicate that the abnormality of platelet membrane GPIV is a common marker in CML, therefore the specific increase of platelet GPIV in patients with CML may be a useful tool for the diagnosis and monitoring of the platelet dysfunction. The release of internal TSP pools is hindered by either β-TG or PF4 in sera. This project was supported by the National Natural Science Foundation of China (No. 39370322).     

Effect of Shengmai injection (生脉注射液) on vascular endothelial and heart functions in patients with coronary heart disease complicated with diabetes mellitus

Objective： To study the effect of Shengmai injection （生脉注射液, SMI） on vascular endothelial and heart functions in coronary heart disease patients complicated with diabetes mellitus （CHD-DM）. Methods： One hundred and twenty patients with CHD-DM, their diagnosis confirmed by coronary arteriography, were equally randomized into a control group treated with conventional treatment and a treated group treated with conventional treatment plus SMI. The changes in blood levels of nitric oxide （NO）, endothelin-1 （ET-1） and angiotensin Ⅱ （Ang Ⅱ）, as well as endothelium-dependent vascular dilating function and heart function in the patients were observed before treatment and after the 3-week treatment. Results： After being treated with SMI for 3 weeks, in the treated group, blood level of NO was raised significantly from 69.8±33.1 μmol/L to 120.1±50.8μmol/L, and ET-1 was lowered from 70.1±32.1 ng/L to 46.2±21.3 ng/L, respectively （P〈0.01）; that of Ang Ⅱ was lowered from 81.3±24.3 ng/L to 50.2±27.3 ng/L （P〈0.01）; brachial arterial post-congestion blood flow increasing rate was raised from 389.4±26.3% to 459.3±27.8% （P〈0.01）; and the improvement in heart function as seen through the ejection fraction （EF） was increased from 44±5% to 68±6% （P〈0.01）, all the changes being more significant than those in the control group （all P〈0.01）. Conclusion： SMI can improve not only the endothelial function in CHD-DM patients, but also heart contraction significantly.     

癌胚抗原相关细胞黏附分子源性多肽KM17对血小板活化作用的研究

目的 探讨癌胚抗原相关细胞黏附分子（CEACAM1）源性多肽KM17对血小板聚集、释放、黏附功能的影响。方法 采用血小板聚集仪观察多肽KM17对凝血酶、胶原、花生四烯酸（AA）、二磷酸腺苷（ADP）等激动剂诱导的血小板聚集的影响;流式细胞术观察多肽KM17对ADP激活血小板后P-选择素释放的影响;显微镜下观察多肽KM17对血小板静态黏附于胶原基质的影响。结果 多肽KM17能显著促进ADP诱导的血小板聚集且呈剂量依赖（P <0.05）,而对AA、胶原及凝血酶诱导的血小板聚集差异均无统计学意义（P>0.05）;此外,多肽KM17对ADP激活血小板后P-选择素释放及血小板静态黏附于胶原基质的差异也无统计学意义（P>0.05）。结论 多肽KM17可明显促进ADP诱导的血小板聚集,但对ADP活化血小板后P-选择素释放及血小板静态黏附于胶原基质未见明显作用。     

Effects of intraoperative autologous blood donation and tepid temperature cardiopulmonary bypass on blood system

We have reported previously that routine cardiopulmonary bypass (CPB) causes platelet count reduced and platelet function h....dlil. Modificationsto routine CPB should be made in order to reduce theharmful non--physiological low temperatUre of CPB tothe blood system and reduce postoperative non--surgical bleeding and blood transfusion needed. The present clinical experiment was designed to investigateintraoperative autologous blood donation and tepidtemperature CPB and compared with routi…     

Effects of POH in Combination with STI571 on the Proliferation and Apoptosis of K562 Cells

Sofar ,the 2 phenylaminopyrimidineSTI5 71isthemostsuccessfulofthemolecularlydesignedATPcompetitorsfromNovartisPharma (Basel,Switzer land) ,whichspecificallyinhibitsAbltyrosinekinaseatmicromolarconcentrations .InhibitionoftheBcr Ablkinaseactivitybythiscom…